
Saturday, September 10, 2022 4:43:43 PM
Hangs a bit but loads
Liked By
Spread the love. Be the first to like this post!
Recent BMY News
- Bristol Myers Squibb Announces Perioperative Regimen of Neoadjuvant Opdivo (nivolumab) and Chemotherapy Followed by Adjuvant Opdivo Significantly Improves Event-Free Survival in Patients with Resectable Non-Small Cell Lung Cancer • Business Wire • 09/22/2023 10:59:00 AM
- Bristol Myers Squibb Announces Dividend • Business Wire • 09/20/2023 10:59:00 AM
- Samsung Biologics announces expanded strategic agreement with Bristol Myers Squibb to manufacture an antibody cancer drug substance • PR Newswire (US) • 09/17/2023 11:57:00 PM
- Friday’s Wall Street Highlights: Ford Motor, Arm, Salesforce, Adobe, Visa, MGM and more • IH Market News • 09/15/2023 01:32:41 PM
- Bristol Myers Squibb Highlights Advancing Pipeline and Differentiated Research Platforms to Support Long-Term Sustainable Growth at R&D Day • Business Wire • 09/14/2023 12:30:00 PM
- Six-Year Outcomes from Phase 3 CheckMate -227 Trial Show Durable, Long-Term Survival with Opdivo (nivolumab) Plus Yervoy (ipilimumab) in the First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer • Business Wire • 09/11/2023 10:59:00 AM
- Bristol Myers Squibb’s Investigational LPA1 Antagonist Reduces Rate of Lung Function Decline in Progressive Pulmonary Fibrosis Cohort of Phase 2 Study • Business Wire • 09/09/2023 10:01:00 PM
- Bristol Myers Squibb Celebrates a Decade of Its Coast 2 Coast 4 Cancer Cross-Country Bike Ride in Support of the V Foundation for Cancer Research • Business Wire • 09/07/2023 11:00:00 AM
- Bristol Myers Squibb to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference • Business Wire • 09/01/2023 10:59:00 AM
- U.S. FDA Approves Bristol Myers Squibb’s Reblozyl® (luspatercept-aamt) as First-Line Treatment of Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (MDS) Who May Require Transfusions • Business Wire • 08/29/2023 02:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/28/2023 09:28:48 PM
- Long-Term Follow-Up Data from Two Phase 3 Studies of CAMZYOS® (mavacamten) Demonstrate Consistent and Durable Response in Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy (HCM) • Business Wire • 08/28/2023 03:26:00 PM
- Cellares Announces Bristol Myers Squibb has Joined Technology Adoption Partnership Program to Evaluate Automated Manufacturing of CAR-T Cell Therapy on the Cell Shuttle Platform • PR Newswire (US) • 08/28/2023 12:00:00 PM
- Retrospective Observational Study Assessing Real-World Clinical Impact of Switching or Continuing Eliquis® or Rivaroxaban Presented at the European Society of Cardiology (ESC) Congress 2023 • Business Wire • 08/25/2023 02:22:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/24/2023 06:17:32 PM
- Bristol Myers Squibb Shares Progress Toward Its Environmental, Social, and Governance Initiatives and Its Health Equity Commitments • Business Wire • 08/23/2023 11:55:00 AM
- BMY Gets European Approval for Opdivo as Treatment for Some Melanoma Patients • Dow Jones News • 08/22/2023 09:08:00 PM
- Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) as an Adjuvant Treatment for Patients with Completely Resected Stage IIB or IIC Melanoma • Business Wire • 08/22/2023 08:18:00 PM
- Bristol Myers Squibb to Showcase Data Across its Innovative Cardiovascular Portfolio at the European Society of Cardiology Congress 2023 • Business Wire • 08/21/2023 10:59:00 AM
- Updated Data from TRIDENT-1 Trial Show Durable Efficacy Benefits with Repotrectinib for Patients with Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer • Business Wire • 08/16/2023 02:19:00 PM
- Bristol Myers Sets $4 Billion Accelerated Stock Buyback • Dow Jones News • 08/10/2023 11:53:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/10/2023 11:10:26 AM
- Bristol Myers Squibb Inducted into the Billion Dollar Roundtable, Expands Supplier Diversity Efforts • Business Wire • 08/10/2023 11:01:00 AM
- Bristol Myers Squibb Enters Into $4 Billion Aggregate Accelerated Share Repurchase Agreements • Business Wire • 08/10/2023 10:59:00 AM
- Bristol Myers Squibb Launches Clear Understanding Campaign to Reveal the Plain Truth About Living with Moderate to Severe Plaque Psoriasis • Business Wire • 08/08/2023 10:59:00 AM
Green Egg to launch $150 million bond offer for quicklime products production kiln plant Sep 22, 2023 12:11 PM
Nate's Food Co. Announces Reverse Merger and Change of Control with JP Energy Group to Drive Global Expansion • NHMD • Sep 22, 2023 9:00 AM
Trio Petroleum Corp Provides Update on Testing of the HV-1 Discovery Well • TPET • Sep 21, 2023 9:38 AM
Pathways to Progress: How Orphan Drug Designation Sparks Biotech Transformation • GNPX • Sep 20, 2023 8:45 AM
Caduceus Provides Update on Its Plans for The Second Half of The Fiscal Year • CSOC • Sep 20, 2023 8:26 AM
RESILIENT ENERGY INC. (RENI) PURSUING ACQUISITION TARGETS • RENI • Sep 19, 2023 10:30 AM